BioStem Technologies, Inc. (BSEM)
Market Cap | 248.98M |
Revenue (ttm) | 210.49M |
Net Income (ttm) | 15.85M |
Shares Out | 16.65M |
EPS (ttm) | 0.82 |
PE Ratio | 18.26 |
Forward PE | 7.40 |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 19,961 |
Average Volume | 56,295 |
Open | 15.00 |
Previous Close | 14.95 |
Day's Range | 15.00 - 15.69 |
52-Week Range | 4.46 - 28.26 |
Beta | 1.45 |
RSI | 51.80 |
Earnings Date | Apr 1, 2025 |
About BioStem Technologies
BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical pr... [Read more]
Financial Performance
In 2023, BioStem Technologies's revenue was $16.69 million, an increase of 142.69% compared to the previous year's $6.88 million. Losses were -$8.48 million, 17.9% more than in 2022.
Financial StatementsNews
BioStem Technologies Launches Clinical Trial to Demonstrate the Therapeutic Benefits of its BioREtain® Technology in Treating Diabetic Foot Ulcers Using Vendaje®
POMPANO BEACH, Fla., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies CEO to Present at Biotech Showcase 2025
POMPANO BEACH, Fla., Jan. 02, 2025 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Announces Notice of Allowance for U.S. Patent Application for Sterile Human Placental Allografts
POMPANO BEACH, Fla., Nov. 25, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacturing, and commercialization of placental-d...
BioStem Technologies Signs Letter of Intent to Acquire Wound Care Products and Technologies from ProgenaCare Global
POMPANO BEACH, Fla., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-deri...
Long-Term, BioStem Technologies Still A Promising Growth Stock
BioStem Technologies has experienced significant price volatility, driven by positive news and uplisting plans, but recent profit-taking has caused a pullback. Q3 earnings report showed impressive gro...
BioStem Technologies, Inc. (BSEM) Q3 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executive Offi...
BioStem Technologies Initiates Nationwide Launch of Vendaje AC® with Venture Medical Following Established Reimbursement in All Medicare Administrative Contractor (MAC) Regions
POMPANO BEACH, Fla., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-deri...
BioStem Technologies to Present at the LD Micro Main Event XVII on Wednesday, October 30, 2024, at 9:30 AM PT
Presentation to be webcast, with management participating in 1-on-1 meetings at the Luxe Sunset Boulevard Hotel in Los Angeles Pompano Beach, Florida--(Newsfile Corp. - October 23, 2024) - BioStem Tec...
BioStem Technologies, Inc. to Present at the H.C. Wainwright 26th Annual Global Investment Conference in New York on September 9th at 3:30 PM ET
POMPANO BEACH, Fla., Aug. 29, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC: BSEM), a leading MedTech company focused on the development, manufacture, and commercialization of placental-der...
BioStem Technologies: A New Growth Star In Health Care
BioStem Technologies has enjoyed exceptional growth in its first year as a public company, with revenues soaring and earnings turning positive. The company's flagship product, AmnioWrap2, has been a m...
BioStem Technologies, Inc. (BSEM) Q2 2024 Earnings Call Transcript
BioStem Technologies, Inc. (OTCPK:BSEM) Q2 2024 Results Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Adam Holdsworth - Investor Relations Jason Matuszewski - Chief Executiv...
BioStem Technologies Inc. In A Race To The Top With Innovative Wound-Care Treatments
Miami, Florida--(Newsfile Corp. - July 16, 2024) - Innovation is the lifeblood of the MedTech sector. Literally.
UPDATE -- PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
Please note: this Update is being issued for ticker indexing purposes. The content of the release itself remains the same.
PRISM MarketView Showcases BioStem Technologies: Impressive Revenue Growth and Strategic Expansion
NEW YORK, June 17, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView presents an exclusive interview with Jason Matuszewski, CEO of BioStem Technologies, Inc. ( OTC: BSEM). Following a successful start to 20...
Biostem Technologies, Inc. (BSEM) Q1 2024 Earnings Call Transcript
Biostem Technologies, Inc. (OTCPK:BSEM) Q1 2024 Earnings Conference Call May 14, 2024 4:30 PM ET Company Participants Jeff Ramson - IR, PCG Advisory Group Jason Matuszewski - Chief Executive Officer M...
BioStem Technologies Retains Clinical Research Industry Veteran Nick McCoy to Lead DFU and VLU trials for BioREtain Allografts
POMPANO BEACH, Fla., April 30, 2024 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
Biostem Technologies, Inc. (BSEM) Q4 2023 Earnings Call Transcript
Biostem Technologies, Inc. (BSEM) Q4 2023 Earnings Call Transcript
Center for Medicare Services Established National Pricing of AmnioWrap2™ in All MAC Regions
POMPANO BEACH, Fla., Dec. 14, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (OTC: BSEM), a leading regenerative medicine company focused on the development, manufacture, and commercialization of ...
NovaBay Pharmaceuticals Announces Commercial Launch of Avenova® Allograft
EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces the commercial launch of Avenova Allograft to eyecare professionals across the U...
NovaBay Pharmaceuticals Announces Agreement with BioStem Technologies to Commercialize Amniotic Tissue Allograft as Avenova® Allograft
EMERYVILLE, Calif. & POMPANO BEACH, Fla.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and BioStem Technologies, Inc. (OTC: BSEM) announce an agreement under which NovaBay has b...
BioStem Awarded a Spot on ECAT, DAPA, and FSS Contract Vehicles Through SDVOSB, Lovell
PENSACOLA, FL, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Lovell® Government Services (‘Lovell') and BioStem Technologies (POMPANO BEACH, FL, ‘BioStem') announced today that they have successfully listed BioS...
BioStem Technologies Commends OIG's Recommendation for CMS to Address ASP Reporting Requirements for Skin Substitute Products
POMPANO BEACH, FLORIDA., March 23, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies (“BioStem” or the “Company”) (OTCQB: BSEM), a leading provider of innovative regenerative medicine solutions, is commen...
BioStem Technologies to Acquire Majority of Assets of Auxocell Laboratories, Inc.
POMPANO BEACH, FLORIDA., March 07, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (“BioStem” or the “Company”) (OTCQB: BSEM), announced today that it has entered into an Agreement to acquire the m...
BioStem Technologies Enters Into a Share Exchange Agreement
The Company will Acquire Back 10% of Issued and Outstanding Shares of its Non-Wholly Owned Subsidiary and Manufacturing Division
BioStem Technologies Poised for Growth with Two New Hires: Michael Sylvester Joins as Vice President of Sales, Neal Bhattacharya as Vice President of Marketing
POMPANO BEACH, FLORIDA., Feb. 01, 2023 (GLOBE NEWSWIRE) -- BioStem Technologies Inc. (“BioStem” or the “Company) (OTCQB: BSEM), a leading regenerative medicine company focused on the development, manu...